What is CONMED's SG&A?

CONMED (CNMD) reported SG&A of $141.7M in Q1 2026.

How has CONMED's SG&A changed year-over-year?

CONMED's SG&A decreased by 4.8% year-over-year, from $148.85M to $141.7M.

What is the long-term trend for CONMED's SG&A?

Over 4 years (2021 to 2025), CONMED's SG&A has grown at a 9.3% compound annual growth rate (CAGR), from $414.75M to $591.97M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

CONMED CNMD SG&A

SG&A at other companies

Johnson & JohnsonJNJ

$6.03B+18.0%

StrykerSYK

$2.28B-0.8%

Boston ScientificBSX

$1.78B+11.5%

VericelVCEL

$49.23M+17.8%

OSI SystemsOSIS

$71.49M-2.4%

Zimmer Biomet HoldingsZBH

$849.9M+12.0%

Other financials

Income statement

See full

Revenue$317.0M-1.3%

Gross profit$183.4M+3.2%

Operating income$25.4M+59.3%

Net income$13.8M+129%

EPS (diluted)$0.45+137%

Balance sheet

See full

Cash & equivalents$35.0M-1.3%

Total debt$862.6M-3.6%

Total equity$1.0B+4.1%

Total assets$2.3B+0.8%

Cash flow

See full

Operating cash flow$13.5M-67.6%

CapEx$2.9M-23.5%

Free cash flow$10.6M-72.0%

Valuation

See full

Market cap$1.07B-35.6%

Enterprise value$1.89B-24.5%

P/E19.4×+5.5×

P/S0.8×-0.5×

Profitability

See full

Gross margin55.2%-1.0pp

Operating margin8.2%-5.6pp

Net margin4%-5.0pp

FCF margin9%-3.5pp

Returns & leverage

See full

Return on equity5.5%-7.5pp

Debt / equity0.8×-0.1×

Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CONMED's SG&A?: CONMED (CNMD) reported SG&A of $141.7M in Q1 2026.
How has CONMED's SG&A changed year-over-year?: CONMED's SG&A decreased by 4.8% year-over-year, from $148.85M to $141.7M.
What is the long-term trend for CONMED's SG&A?: Over 4 years (2021 to 2025), CONMED's SG&A has grown at a 9.3% compound annual growth rate (CAGR), from $414.75M to $591.97M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.